DNA-Protein Crosslinks Drive Inflammation Linked to Early Aging

Why It Matters

Linking a specific DNA lesion to innate immune activation reveals a tractable target for treating progeroid syndromes and potentially broader age‑associated diseases.

Key Takeaways

• Unrepaired DPCs trigger cGAS‑STING inflammation.
• SPRTN deficiency causes micronuclei and embryonic lethality.
• Inhibiting cGAS‑STING rescues premature aging phenotypes.
• DPC accumulation links DNA damage to progeria.
• Early developmental defects set aging trajectory.

Pulse Analysis

DNA‑protein crosslinks (DPCs) arise when proteins become covalently attached to DNA, creating bulky lesions that obstruct replication and transcription. Unlike classic double‑strand breaks, DPCs demand specialized proteolytic removal, a role fulfilled by the SPRTN metalloprotease during S‑phase and mitosis. Failure to clear these lesions compromises genome integrity, prompting chromosome mis‑segregation and the formation of micronuclei—small, extranuclear bodies that house damaged DNA fragments. The new mouse model underscores how SPRTN mutations, which mirror the human Ruijs‑Aalfs progeria syndrome, precipitate systemic DPC buildup and set the stage for downstream pathology.

The accumulation of DPC‑laden micronuclei activates the cytosolic DNA sensor cGAS, which in turn engages the STING adaptor to launch a type I interferon response. This innate immune signaling cascade converts a DNA‑repair defect into chronic inflammation, a hallmark of accelerated aging. Notably, the study demonstrates that embryonic lethality and progeroid features can be mitigated by pharmacologically dampening cGAS‑STING activity, highlighting a direct mechanistic bridge between early developmental DNA damage and lifelong degenerative outcomes.

Therapeutically, the work opens a dual‑frontier: enhancing DPC repair capacity and modulating innate immune pathways. Small‑molecule SPRTN activators or gene‑therapy approaches could restore proteolytic clearance, while cGAS‑STING inhibitors—already in clinical trials for autoimmune disorders—may be repurposed for progeroid conditions. Beyond rare syndromes, the findings suggest that subclinical DPC accumulation might contribute to normal aging and age‑related diseases, prompting biotech firms to explore biomarkers of DPC burden and novel anti‑inflammatory strategies aimed at preserving genomic fidelity.